Drug Details

General Information of the Drug (ID: DR0043)
Name
Ofloxacin
Synonyms
ofloxacin; 82419-36-1; Floxin; Ofloxacine; Tarivid; Ocuflox; OFLX; Ofloxacino; Ofloxacinum; Exocin; Hoe-280; DL-8280; Floxin otic; HOE 280; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; Oxaldin; Dextrofloxacin; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; DL-ofloxacin; CHEBI:7731; Oflocet; Visiren; CHEMBL4; MFCD00226105; MLS000028749; Ofloxacina; Ofloxacin Otic; Ofloxacin, 98%; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacinum [Latin]; Exocine; Flobacin; SMR000058192; Zanocin; Floxil; Ofloxacino [Spanish]; DSSTox_CID_21085; DSSTox_RID_79623; DSSTox_GSID_41085; 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid; OFX; C18H20FN3O4; FLOXIN IN DEXTROSE 5%; DL 8280; MFCD00865049; PT 01; ORF 18489; (-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1;(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; Floxin (TN); CCRIS 5233; (+/-)-Floxin; SR-01000076050; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; BRN 3657947; Monoflocet; ofloxacin;; Ofloxacin-d3; HSDB 8030; J01MA01; Ofloxacin,(S); NCGC00016948-01; Ofloxacin (Floxin); CAS-82419-36-1; Exocin (eye drops); Ofloxacin [USAN:USP:INN:BAN:JAN]; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; WP-0405; Spectrum_001186; (R)-Ofloxacin-[d3]; Opera_ID_1114; Prestwick0_000237; Prestwick1_000237; Prestwick2_000237; Prestwick3_000237; Spectrum2_001464; Spectrum3_001499; Spectrum4_000324; Spectrum5_001063; ACMC-20m40v; Epitope ID:116889; O 8757; Lopac0_000904; Oprea1_242882; SCHEMBL24373; BSPBio_000313; BSPBio_003117; KBioGR_000667; KBioSS_001666; fluoro-methyl-(4-methylpiperazin-1-yl)-oxo-[?]carboxylic acid; MLS001074203; MLS006011774; DivK1c_000721; SPECTRUM1502044; SPBio_001387; SPBio_002234; (S)-Ofloxacin;Levaquin;Quixin; Ofloxacin (JP17/USP/INN); BPBio1_000345; DTXSID3041085; SCHEMBL14163982; GTPL10918; HMS502E03; KBio1_000721; KBio2_001666; KBio2_004234; KBio2_006802; KBio3_002617; NINDS_000721; HMS1568P15; HMS1921H12; HMS2090F07; HMS2092B10; HMS2095P15; HMS2235C05; HMS3259G07; HMS3262F10; HMS3369B01; HMS3393K06; HMS3604B17; HMS3712P15; Pharmakon1600-01502044; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3R)-; AMY22220; BCP14346; BCP22048; EBD13209; HY-B0125; RKL10083; Ofloxacin, fluoroquinolone antibiotic; Tox21_110703; Tox21_500904; BBL005605; BDBM50045004; CCG-39210; NSC727071; NSC758178; s1463; STK256723; AKOS001033517; AKOS016042783; Ofloxacine; DL-8280; HOE-280; Tox21_110703_1; AC-7616; BCP9000851; CS-1891; DB01165; KS-5011; LP00904; NC00466; NSC 727071; NSC 758178; NSC-727071; NSC-758178; SDCCGSBI-0050879.P004; VA11432; IDI1_000721; NCGC00015772-02; NCGC00015772-03; NCGC00015772-04; NCGC00015772-05; NCGC00015772-06; NCGC00015772-07; NCGC00015772-08; NCGC00015772-09; NCGC00015772-10; NCGC00015772-12; NCGC00015772-13; NCGC00015772-22; NCGC00094219-01; NCGC00094219-02; NCGC00094219-03; NCGC00094219-04; NCGC00094219-05; NCGC00094219-06; NCGC00178284-01; NCGC00178284-02; NCGC00261589-01; Ofloxacin 100 microg/mL in Acetonitrile; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)-; 83380-47-6; 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic Acid; AK163167; AK163316; H778; ST073364; SY007392; SBI-0050879.P003; AB0013254; DB-056608; AB00513820; EU-0100904; FT-0627808; FT-0630905; FT-0670773; FT-0673216; O0403; Ofloxacin, VETRANAL(TM), analytical standard; VU0243192-7; 86O854; A10666; C07321; D00453; J10376; O-2800; W-3058; AB00052263-12; AB00052263-13; AB00052263_14; AB00052263_15; Ofloxacin, Antibiotic for Culture Media Use Only; Q411447; SR-01000076050-1; SR-01000076050-4; SR-01000076050-7; BRD-A24228527-001-05-9; BRD-A24228527-001-19-0; Z56761309; F0020-0095; F0472-0226; 138199-71-0 (0.5H2O); 7-Chloro-4-hydroxy-8-methylquinoline-3-carboxylicethylester; Ofloxacin, European Pharmacopoeia (EP) Reference Standard; Ofloxacin, United States Pharmacopeia (USP) Reference Standard; (+/-)-9-Fluoro-2,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 8-Methyl-2,3-dihydrofuro[3,2-e]imidazo-[1,2-c]pyrimidine-9-carboxylicacid; Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material; ()-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoazine-6-carboxylic acid; (+/-)-9-Fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (3R)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; 7-Fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-Fluoro-10-(4-methylpiperazino)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzooxazine-6-carboxylic acid; 9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de]-1,4-Benzoxazin-6-carboxylic Acid; 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 9-fluoro-3-methyl-10-(4-methylpiperazino)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Bioavailability
The bioavailability of drug is 98%
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.5 mL/min/kg
Elimination
64% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 9 hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 31.6248 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.75%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.6 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 3.54 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C18H20FN3O4
PubChem CID
4583
Canonical SMILES
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
InChI
1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
InChIKey
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
CAS Number
CAS 82419-36-1
ChEBI ID
CHEBI:7731
TTD Drug ID
D03NHW
DrugBank ID
DB01165
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Cefixime      Acremonium chrysogenum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Salmonella Typhimurium Microorganism model Salmonella Typhimurium
                    Experimental
                    Result(s)		 Cefixime-ofloxacin combination could be effective against moderately susceptible fluoroquinolone S. Typhi but not fluoroquinolone-resistant isolates.
    β. A List of Natural Product(s) Able to Reverse the Resistance of This Drug
          Propolis      Streptophyta     Click to Show/Hide the Molecular Data of This NP
                 Reversing Drug Resistance     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Escherichia coli isolates NECS892841 Microorganism model Escherichia coli
Escherichia coli isolates NECS30090 Microorganism model Escherichia coli
Escherichia coli isolates NECS858785 Microorganism model Escherichia coli
Escherichia coli isolates NECS864598 Microorganism model Escherichia coli
Escherichia coli isolates NEC892420 Microorganism model Escherichia coli
Escherichia coli isolates NEC118564 Microorganism model Escherichia coli
                    Experimental
                    Result(s)		 Propolis could enhance the efficiency of antibiotics used in UTIs and could represent an alternative solution.
Target and Pathway
Target(s) Bacterial DNA gyrase (Bact gyrase)  Molecule Info  [4]
References
Reference 1 Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
Reference 2 In vitro efficacy and in silico analysis of cefixime-ofloxacin combination for Salmonella Typhi from bloodstream infection. J Appl Microbiol. 2017 Sep;123(3):615-624.
Reference 3 Synergistic Effect of Propolis and Antibiotics on Uropathogenic Escherichia coli. Antibiotics (Basel). 2020 Oct 27;9(11):739.
Reference 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link